Repare Therapeutics Inc
1 day chart
Repare Therapeutics Inc. is a clinical-stage precision oncology company. The Company is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. It uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
Buy US stocks in Australia with $0 brokerage and trade RPTX today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.